Reproductive problems encompass a multiplicity of diseases including sterility, infertility, abortion (miscarriage), stillbirth, congenital malformations (resulting from environmental or hereditary etiologies), fetal growth retardation, and prematurity. These clinical problems occur commonly in the general population and, therefore, environmental causes are not always easy to corroborate (Table 15 .1). Severe congenital malformations occur in 3 % of births; according to the Center for Disease Control, they include those birth defects that cause death, hospitalization, and mental retardation, and those that necessitate significant or repeated surgical procedures, are disfiguring, or interfere with physical performance. This means that each year in the USA, 120000 babies are born with severe birth defects. Genetic disease occurs in approximately 11 % of births, and spontaneous mutations account for approximately 2-3% of genetic disease. This spontaneous mutation rate presents difficulties when determining the proportion of mutations that are induced from preconception exposure to environmental mutagens.
There have been dramatic advances in our-understanding of the causes of human birth defects. In earlier times, superstition, ignorance, and prejudice played a major role in explain-.ing why birth defects occurred. Reproductive problems have been viewed throughout history as diseases of affliction, along with cancer, psychiatric illness, and hereditary diseases. The stigma associated with birth defects has primitive beginnings and persists today; in the minds of many, even the most sophisticated, a birth defect is felt to be some form of punishment for previous misdeeds.14 Ancient Babylonian writings recount tales of mothers being put to death because they delivered malformed infants. In the seventeenth century, one George Spencer was slain by the Puritans in New Haven having been convicted of fathering a cyclopean pig; the Puritans were unable to differentiate between George Spencer's cataract and the malformed pig's cloudy cornea.' More recently, the situation has been reversed and the responsibility for reproductive problems such as congenital malformations, infertility, abortions, and hereditary diseases is often blamed on others, for example, environmental agents dispensed by healthcare providers or utilized by emp10yers.l.~ Reproductive problems alarm the public, the press, and scientists to a greater degree than many other diseases. Severely malformed children are disquieting to healthcare providers, especially if they are not experienced in dealing with such problems; no physician will be comfortable informing a family that their child was born without arms and legs. The objective evaluation of the environmental causes of reproductive diseases is clouded by the emotional climate that surrounds these diseases, resulting in the expression of partisan positions that either diminish or magnify the environmental risks. These nonobjective opinions can be expressed by scientists, the laity, or the It is the responsibility of every physician to be aware of the emotionally charged situation when a family has a child with a birth defect; an inadvertent comment from medical staff attending delivery can have grave consequences for the physician and the family. Comments such as, "Oh, you had a radiograph during your pregnancy," or "You did not tell me that you were prescribed tetracycline while you were pregnant," can direct the patient's family to an attorney rather than to a teratology or genetic counselor. .
At present, the etiology of congenital malformations can be divided into three categories: unknown, genetic, and environmental. Unfortunately, the largest group has an unknown etiology, whereas the most common known cause is genetic (15-25%).7-9 Environmental factors account for 10% of congenital malformations. Over 50 teratogenic environmental drugs, chemicals, and physical agents have been described9-l2 by clinical dysmorphologists using modern epidemiological tool^.'^-'^ The basic science and clinical rules for evaluating teratogenic risks have been e~tablished.~' The purpose of this chapter is to inform clinicians about environmental drugs, chemicals, and physical agents that have been documented to produce congenital malformations and reproductive effects, and to indicate that the multdude of teratogenic agents accounts for only a small proportion %f malformations. 'The mutation rate for many genetic diseases can be calculated; this can be readily performed with dominantly inherited diseases when offspring are born with a dominant genetic disease and neither parent has the disease. tcongenital malformations have multiple etiologies including a significant proportion that are genetic.
Basic principles of teratology
To label a n environmental agent as teratogenic it is necessary to characterize the dose, route of exposure, and stage of pregnancy when the exposure occurred. A SO-mg dose of thalidomide administered on the 26th day post conception has a significant risk of maiforming the embryo. The same dose taken during the 10th week of gestation will not result in congenital malformations, and I mg of thalidomide taken a t any time during pregnancy will have no effect o n the developing embryo. X-ray irradiation can be t e r a t o g e n i~;~' -~~ however, if the dose is too low or the X-ray does not directly expose the embryo, there is no increased risk of congenital malformat i o n~.~ Therefore a list of teratogens indicates only teratogenic potential; evaluation of the dose and time of exposure may indicate that there is no teratogenic risk or that the risk is significant.
Physicians must be careful to carry out a thorough evaluation of the risks faced by a woman exposed to drugs and chemicals during pregnancy, and before alleging that a child's malformations result from exposure to a n environmental agent. Clinical teratology and genetics is not emphasized in medical schools and residency education programs. However, clinicians have a multitude of educational aids to assist them in their evaluations; these include consultations with clinical teratologists and geneticists, the medical literature, and the Online Mendelian Inheritance of Man (OMIM) ~e b s i t e . '~ The analysis of human and animal studies on the reproductive effects of environmental agents should be guided by the basic principles of teratology and developmental b i~l o g y ;~ these principles are outlined in Table 15 .2.2s"2
The etiology of congenital malformations
As mentioned earlier, the etiology of congenital malformations can be divided into three categories: unknown, genetic, and environmental (Table 15. 3). A significant proportion of congenital malformations of unknown etiology are likely to have an important genetic component. Mhlformations with an increased recurrent risk such as cleft lip and palate, anencephaly, spina bifida, certain congenital heart diseases, pyloric stenosis, hypospadias, inguinal hernia, talipes equinovarus, and congenital dislocation of the hip fit into the category of multifactorial disease as well as that of polygenic inherited d i~e a s e .~~,~~ The multifactoriaVthreshold hypothesis postulates the modulation of a continuum of genetic characteristics by intrinsic and extrinsic (environmental) factors.
A significant percentage of spontaneous errors of development can occur without apparent abnormalities of the genome or environmental influences; these are due to the statistical probability of errors in the developmental process, similar to the concept of spontaneous mutation, and mean that we may never achieve our goal of eliminating birth defects. It is esti-, mated that the majority of all miscarriages occur early in pregnancy, many within the first 3 weeks of deve!opment. The World Health Organization estimated that 1 5 % of all clinically recognizable pregnancies end in spontaneous abortion, 
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Exposure to teratogens follows a toxicological There is a threshold below which no teratogenic effect will be observed. As the dose-response curve dose of the teratogen is increased, both the severity and frequency of reproductive effects will increase ( Fig. 15.1 
Factors that affect susceptibility to developmental toxicants
A basic tenet 'of environmentally produced malformations is that teratogens o r a teratogenic milieu have certain characteristics in c o m m o n a n d follow certain basic principles. These principles determine the quantitative and qualitative aspects of environmentally produced malformations.
Embryonic stage
T h e risk of a n exposure to a developmental toxicant resulting in morphological anomalies o r intrauterine death depends o n the dose a n d the embryonic o r fetal stage a t which exposure occurs. T h e period when a n exposure occurs will determine which structures are most susceptible t o the deleterious effects CHAPTER 1 5 Table 15 . 4 Developmental stage sensitivity to thalidomide-induced limb reduction defects in the human.
Days from conception Limb reduction defects ' for induction of defects
21-26
Thumb aplasia
22-23
Microtia, deafness
23-34
Hip dislocation
4 9
Amelia, upper limbs
24-33
Phocomelia, upper limbs
25-31 -
Preaxial aplasia, upper limbs
27-31
Amelia, lower limbs
28-33
Preaxial aplasia, lower limbs; phocomelia, lower limbs; femoral hypoplasia; girdle hypoplasia 
33-36
Triphalangeal thumb
Modified from ref. Table 15 .4), whereas microcephaly, produced by radiation, has a long period of susceptibility (weeks 8-15 of pregnan~y).~ The embryo is most sensitive t o the lethal effects of drugs and chemicals during the period of embryonic development, from fertilization through the early postimplantation stage. Surviving embryos have malformation rates that are similar to those of control subjects because significant cell loss or chromosome abnormalities at these stages has a high likelihood of resulting in embryonic death, not because malformations cannot be produced a t this stage. Because of the omnipotentiality of early embryonic cells, surviving embryos have a high probability of having malformation rates that are similar to embryos that have not been exposed.
The period of organogenesis (from day 1 8 through about day 40 post conception in the human) is the period of greatest sensitivity to teratogenic insults and when most gross anatomic malformations can be induced. Most environmentally produced major malformations occur before the 36th day post conception in the human. The exceptions are malformations of the genito-urinary system, the palate, and the brain, or deformations due to problems of constraint, disruption or destruction.
The fetal period is characterized by histogenesis involving cell growth, differentiation, and migration. Agents that result in cell depletion, vascular disruption, necrosis, specific tissue or organ pathology, physiological decompensation, or severe growth retardation have the potential to cause deleterious effects throughout gestation. The fetus is most sensitive to the induction of mental retardation and microcephaly at the end of the first and the beginning of the second trimester. Other permanent neurological effects can be induced in the second and third trimesters. Effects such as cell depletion or functional abnormalities, not readily apparent at birth, may give rise to changes in behavior or fertility which are only apparent later in life. The last gestational day on which certain malformations may be induced in the human is presented in Table 15 .5.
Dose or magnitude of the exposure
The quantitative correlation between the magnitude of the embryopathic effects and the dose of a drug, chemical, or other agent is referred to as the dose-response relationship. This is extremely important when comparing effects among different species because the use of mgtkg doses are, a t best, rough approximations. Dose equivalence for drugs and chemicals between humans and other species can be accomplished only by performing pharmacokinetic studies, metabolic studies, and dose-response investigations, whereas'ionizing radiation exposures in rads or sieverts (Sv) are similar in most mammalian species.' The response should be interpreted carefully. For example, a substance given in large enough amounts to cause maternal toxicity is also likely to have deleterious effects on the embryo such as death, growth retardation, or retarded development. Also, it is unlikely that progesterone o r its synthetic analogues are involved in congenital teratogenesis because the steroid receptors that are necessary for naturally occurring and synthetic progestin action are absent from nonreproductive tissues early in d e~e l o p m e n t . '~~' Several considerations affect the interpretation of dose-response relationships and these are outlined in Table 15 .6.
Threshold dose
The threshold dose is the dose b l o w which the incidence of death, malformation, growth retardation,. o r . functional deficit is not statistically greater than that of control subjects ( Fig. 15.1 ). The threshold level oTexposure usually varies between less than one and up to two orders of magnitude below the teratogenic or embryopathic dose for drugs and chemicals that kill or malform one-half of the embryos. An exogenous teratogenic agent, therefore, has a no-effect dose compared with mutagens or carcinogens, which have a stochastic dose-response curve (Table 15 .7, Fig. 15.1) . The incidence and severity of malformations produced by all exogenous teratogenic agents that have been appropriately studied have exhibited threshold phenomena during organogenesis.' The threshold concept stems from the principle that manifestations of developmental toxicity occur because the processes of repair and regeneration have been overwhelmed by a particular exposure to a developmental toxicant. It does not predicate that no effect occurs at lower exposures, just that there is no deleterious or irreversible effect. 
Pharmacokinetics and metabolism of the drug or chemical
Physiological alterations during pregnancy as well as the bioconversion of compounds can significantly influence the teratogenic effects of drugs and chemicals by affecting absorption, body distribution, the active form(s), and excretion of the compound. Tables 15.8 and 15.9 outline the pregnancyrelated physiological alterations in the mother and fetus, respectively, that affect the pharrnacokinetics of drugs.4244
Although other organs, including the placenta, can be involved in the metabolism of drugs or chemicals, the major site of bioconversion of chemicals in vivo is likely to be the maternal liver. Placental P450-dependent monooxygenation of xenobiotics will occur at low rates unless induced by compounds such as those found in tobacco smoke.45 However, the rodent embryo and yolk sac have been shown to possess functional P4SO-oxidative isozymes capable of converting proteratogens to active metabolites during early ~r~a n o g e n e s i s .~~ In addition, P4SO-independent bioactivation has been suggested; for example, there is strong evidence that the rat embryo can reductively convert niridazole to an embryotoxic metabolite?' Bioconversion of xenobiotics has been shown to be important in their teratogenic activity. There is strong evidence that the reactive metabolites of cydophosphamide, 2-acetylaminofluorene, and nitroheterocycles (niridazole) are the proximate teratogens?* There is also experimental evidence suggesting that other chemicals undergo conversion to intermediates that have deleterious effects on embryonic development, for example, phenytoin, procarbazine, rifampicin, diethylstilbestrol, some benzhydrylpiperazine antihistamines, adriamycin, testosterone, benzo(a)pyrene, methoxyethanol, caffeine, and paraq~at.~'*~* " Juchau4' has defined several experimental criteria to suggest that a suspected metabolite is responsible for the in uiuo teratogenic effects of a chemical or drug (Table 15 .10). These criteria may explain why there are marked qualitative and quantitative differences in the species response to a teratogenic agent.
Placental transport
It has been suggested that the placental barrier is protective and that harmful substances do not reach the embryo; however, it is now clear that there is no "placental barrier" per se. The package inserts on many drugs state that "this drug 'crosses the placental barrier"6 and the uninitiated may infer from this statement that this characteristic of a drug is both unusual and hazardous. However, most drugs and chemicals cross the placenta, and only selected proteins, whose actions are species specific, will cross the placental barrier in one species but not another. The role that the placenta plays in drug pharmacokinetics has been reviewed by Juchau and Rettie4' and involves: (1) transport; (2) the presence of receptor sites for a number of endogenous and xenobiotic compounds (P-adrenergic agents, glucocorticoids, epidermal growth factor, IgG-Fc, insulin, lowdensity lipoproteins, opiates, somatomedin, testosterone, transcobalamin 11, transferrin, folate, r e t i n~i d ) ;~~ and (3) the bioconversion of xenobiotics.
The factors which determine the ability of a drug or chemical to cross the placenta and reach the embryo include molecular weight, lipid affinity or solubility, polarity or degree of ionization, protein binding, and receptor mediation. Compounds with a low molecular weight and lipid affinity, nonpolarity, and without protein-binding properties will cross the placenta rapidly and with ease. For example, ethyl alcohol reaches the embryo rapidly and in concentrations equal to or greater than the level in the mother. High-molecular-weight compounds like heparin (20 000 daltons) do not cross the placenta readily and, therefore, during pregnancy, heparin is used instead of warfarin-like compounds for the treatment of hypercoagulation conditions. Rose Bengal does not cross the placenta at all. In general, compounds with molecular weights of 1000 daltons or more do not readily cross the placenta, whereas those less than 600 daltons usually do; most drugs are 250-400 daltons and do cross the pla~enta.'~
Genetic differences
The genetic constitution of an organism is an important factor in the susceptibility of a species to a drug or chemical. More than 30 disorders of increased sensitivity to drug toxicity ,or effects in the human result from an inherited trait." Maternal and fetal genotypes determine the types of bioconversion route, the rate at which bioconversions take place, and the extent to which a compound is metabolized.
however, negative animal studies do not guarantee that Environmental agents resulting in these agents are free from reproductive effects in humans.
reproductive toxicity following exposure
There are examples in which drug testing was negative in ; during pregnancy animals (rat and mouse), but was teratogenic in the human (thalid~mide).~' Similarly, there are examples in which a drug 
Interpretation of animal study data for assessment of reproductive risks in humans
As human studies are expensive and take years t o complete, scientists have investigated the issue of whether appropriate animal models can be used to evaluate the reproductive and toxicological risks of environmental agents in humans (teratogenesis, growth retardation, pregnancy loss, stillbirth, and infertility).
Whole animal teratology studies are helpful in raising concerns about the reproductive effects of drugs and chemicals; was teratogenic in an animal model but not in humans (diflunisal). Therefore, while chemicals and drugs can be evaluated for their toxic potential by utilizing in vivo animal studies and in vitro systems, it should be recognized that these testing procedures are only one component in the process of evaluating the potential toxic risk of drugs and chemicals. Wellperformed epidemiology studies still represent the best methodology for determining the risks and effects of environmental toxicants on humans. Indeed, most human teratogens have been discovered by alert physicians or during epidemiology studies, not animal studies. 62 In vitro studies play an even less important role, although they are helpful in describing the cellular or tissue-specific effects of drugs and chemicals.
One useful aspect of animal studies is in corroborating findings reported in epidemiological studies. Attempts at risk assessment can be made by utilizing toxicokinetic data that have been obtained in an animal model, and exposure levels of the alleged toxicant and its metabolites that have been determined in humans. Studies to elucidate whether the mechanism, of action of a drug or chemical in the animal model is the same as that in humans would further add to the toxicologist's ability to estimate human risks. This is not a simple process and explains why good-quality epidemiological studies are so valuable in determining human risks and toxicity.
Clinicians are given little training in medical school and during residency training on how to interpret animal toxicology studies. This is probably more true of reproductive Many chemotherapeutic agents used to treat cancer have a theoretical risk of producing fetal malformations, as most of these drugs are teratogenic in animals; however, the clinical data are not consistent. Many have not been shown to be teratogenic but the numbers of cases in the studies are small; caution is the byword Genital abnormalities, adenosis, and clear cell adenocarcinoma of the vagina in adolescents. The risk of adenosis can be quite high; the risk of adenocarcinoma is 1:1000 to 1:10000 Fetal alcohol syndrome (microcephaly, mental retardation, growth retardation, typical facial dysmorphogenesis, abnormal ears, and small palpebral fissures) A threshold greater than 20 rad (0.2 G y p a n increase the risk of some fetal effects such as micocephaly or growth retardation. The threshold for mental retardation is higher Microcephaly and mental retardation Chronic use for the treatment of manic depressive illness has an increased risk for Ebstein's anomaly and other malformations, but the risk appears to be very low Hirsutism in newborns (led to the discovery of the hair growth-promoting properties of minoxidil) Aplasia cutis has been reported* Fetal intestinal atresia, hemolytic anemia, and jaundice in the neonatal period. This procedure is no longer utilized to identify one rwin Low incidence of vascular disruptive phenomenon, such as limb reduction defects and Mobius syndrome, has been reported in pregnancies in which this drug was used to induce an abortion This drug results in the physical effects referred to as lathyrism, the results of poisoning by the seeds of the genus Lathyrus. It causes collagen disruption, cutis laxa, and hyperflexibility of joints. The condition appears to be reversible and the risk is low Very high doses of androgen hormone-derived progestins can produce masculinization. Many drugs with progestational activity d o not have masculinizing potential. None of these drugs has the potential for producing congenital malformations Along with other antithyroid medications can result in an infant born with a goiter Tissue-and organ-specific damage is dependent on the radioisotope element and distribution, i.e., high doses of l3'I administered to a pregnant woman can cause fehl thyroid hypoplasia after the 8th week of development Systemic retinoic acid, isotretinoin, and etretinate can result in an increased risk of CNS, cardio-aortic, ear, and clefting defects, microtia, anotia, thymic aplasia and other branchial arch and aortic arch abnormalities, and certain congenital heart malformations This is very unlikely to have teratogenic potential because teratogenic serum levels are not achieved from topical exposure Streptomycin and a group of ototoxic drugs can affect the eighth nerve and interfere with hearing; it is a relatively low-risk phenomenon. Children are even less sensitive to the ototoxic effects of these drugs than adults Hemolysis in some subpopulations of fetuses Bone and teeth staining Increased incidence of deafness, anotia, preaxial limb reduction defects, phocomelia, ventricular septa1 defects, and GI atresias during susceptible period from the 22nd to the 36th day post conception This drug was frequently used to treat urinary tract infections and has been linked to an increased incidence of neural tube defects. The risk is not high, but it is biologically plausible because of the drug's lowering effect on folic acid levels. This has also resulted in neurological symptoms in adults taking this drug Very high doses of vitamin A have been reported to produce the same malformations as those reported for the retinoids. Dosages sufficient to produce birth defects would have to be in excess of 25000 to 50000 units per day Large doses given in vitamin D prophylaxis are possibly involved in the etiology of supravalvular aortic stenosis, elfin facies, and mental retardation Exposure during early pregnancy can result in nasal hypoplasia, stippling of secondary epiphysis, and intrauterine growth retardation. Exposure in late pregnancy can result in CNS malformations as a , result of bleeding Anticonvulsants Carbamazepine Used in the reatment of convulsive disorders; increases the risk of facial dysrnorphology (Continued) CHAPTER 1 5 'used in the treatment of convulsive disorders; increases the risk of fetal hydantoin syndrome, consisting of facial dysmorphology, cleft palate, ventricular septa1 defect (VSD), and growth and mental retardation Used in the treatment of convulsive disorders; increases the risk of characteristic facial dysmorphology, mental retardation, V-shaped eyebrows, low-set ears with anteriorly folded helix, high-arched palate, irregular teeth, CNS anomalies, and severe developmental delay Used in the treatment of convulsive disorders; increases the risk of spina bifida, facial dysmorphology, and autism CNS damage has been reported with very high exposures, but the risk appears to be low Facial dysmorphology, mental retardation Very high exposures can cause pregnancy loss; intrauterine teratogenesis is not established Causes Minamata disease consisting of cerebral palsy, microcephaly, mental retardation, blindness, and cerebellum hypoplasia. Endemics have occurred from adulteration of wheat with mercury-containing chemicals that are used to prevent grain spoilage. Present environmental levels of mercury are unlikely to represent a teratogenic risk, but reducing or limiting the consumption of carnivorous fish has been suggested in order not to exceed the Environmental Protection Agency's (EPA's) maximum permissible exposure (MPE), which is far below the toxic effects of mercury Poisoning has occurred from adulteration of food products (cola-colored babies, CNS effects, pigmentation of gums, nails, teeth and groin, hypoplastic deformed nails, intrauterine growth retardation, abnormal skull calcification). The threshold exposure has not been determined, but it is unlikely to be teratogenic at the present environmental exposures Facial dysmorphology, mental retardation Retinopathy, CNS calcification, microcephaly, mental retardation Fetal infection, liver disease, death Perinatal HIV infection Stillbirth, hydrops Deafness, congenital heart disease, microcephaly, cataracts, mental retardation Maculopapular rash, hepatosplenomegaly, deformed nails, osteochondritis at joints of extremities, . 4 congenital neurosyphilis, abnormal epiphyses, chorioretinitis Hydrocephaly, microphthalmia, chorioretinitis, mental retardation Skin and muscle defects, intrauterine growth retardation, limb reduction defects, CNS damage (very low increased risk) Hydranencephaly, microphthalmia, CNS destructive lesions, luxation of hip Mothers with Cushing's disease can have infants with hyperadrenocortism, but anatomical malformations do not appear to be increased Iodine deficiency can result in embryonic goiter and mental retardation Defects such as club feet, limb reduction, aplasia cutis, cranial asymmetry, external ear malformations, midline closure defects, cleft palate and muscle aplasia, cleft lip, omphalocele, and encephalocele. More common in multiple-birth pregnancies, pregnancies with anatomical defects of the uterus, placental emboli, and amniotic bands Masculinization Caudal and femoral hypoplasia, transposition of great vessels Increased incidence of neural tube defects (NTDs) Abortion, microcephaly, and mental retardation. Very high risk in untreated patients Intrauterine growth retardation, abortion, NTDs Abortion, intrauterine growth retardation, and stillbirth NTDs 
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Evaluating animal studies to determine the potential risk in humans
When utilizing animal data to assess the potential risk of a drug or chemical exposure in humans, it is important to critically evaluate the studies using the basic principles of teratology guidelines (Table 15. 2). As discussed previously, one of the most critical factors for consideration is the dose or magnitude of the exposure, and the concept of the threshold-dose effect for reproductive toxicants. A major shortcoming in many studies is the use of weight (mglkg) as a measure of dose, as dose comparisons based on mglkg doses are, at best, rough approximations. Instead, testing in animals could be improved if drugs and chemicals were administered to achieve pharmacokineticalIy equivalent serum levels in the animal and human. Dose equ~valence between species can be accomplished only by performing pharmacokinetic studies, metabolic studies, and dose-response investigations in the human and the species being studied. Dose equivalence must also be determined for the drug-specific effects at the cellular level, to account for species differences in the molecular targets of chemicals or drugs. An excellent example of the importance of the use of pharmacological, rather than weight-based, dose equivalenck in interpreting animal study data is illustrated by animal and epidemiological studies performed on lefl~nomide.~' Leflunomide is a relatively new drug (1998) which is used to treat rheumatoid arthritis. It contains a warning for reproductive effects (teratogenesis) and has been placed in category X. This classification was based on animal studies as there were no human data available at the.time of marketing.
Leflunomide is a novel isoxazole immunomodulatory agent that has antiproliferative activity. It inhibits mitogenstimulated proliferation of human peripheral blood mononuclear cells (PBMCs) in a dose-dependent fashion. It has been demonstrated that the active metabolite binds to, and is a potent inhibitor of, dihydroorotate dehydrogenase (DHODH), an enzyme important for DNA synthesis in the de novo pyrimidine synthesis pathway. Together, these data suggest that at serum concentrations achievable in patients, leflunomide inhibits de novo pyrimidine synthesis in activated lymphocytes and other rapidly dividing cell populations, resulting in reversible cell cycle arrest.
In oral embryotoxicity and teratogenicity studies in rats and rabbits, leflunomide was embryotoxic (growth retarding, embryolethal, and teratogenic). The no-effect level for embryotoxicity and teratogenicity in rats and rabbits was I mglkg body weight, which resulted in serum levels of 3.7 and 4.1 p d m L respectively. In patients being treated with leflunomide, the active metabolite (the pyrimidine antagonist), is maintained at a blood level of 40pglmL. The decision to label leflunomide as having a teratogenic risk was based on the fact that the human serum level was in the range of the teratogenic blood level in the animal models, and, therefore, the initial labeling was an appropriate precaution to prevent birth defects.
After 4 years of treating rheumatoid arthritic patients with leflunomide there was no indication of an increase in teratogenesis in a very small group of pregnant patients who continued their pregnancy to term. The animal data were, therefore, reanalyzed as follows (referred to as the method of action (MOA) approach). The most likely mechanism of leflunomide teratogenicity is the suppression of DNA synthesis and cell proliferation by the inhibition of pyrimidine synthesis. This is based on the assumption that, at the same serum levels of the active metabolite of leflunomide, suppression of DNA synthesis, pyrimidine synthesis, and cell proliferation is equal in the rat, rabbit, and human. There would then be concurrence and the risks would be determined to be identical in all three species; this was the basis of the X-category labeling. However, in uitro studies on the active metabolite of leflunomide revealed that the rat was 40 and 328 times more sensitive to the suppression of DHODH and cell proliferation, respectively, than the human.32 This means that if enzyme suppression or antiproliferative activity is the mechanism (MOA) of teratogenicity in the rat, then the clinical use of leflunomide in pregnant women would probably not be teratogenic. It is important that this drug is subjected to ongoing epidemiological surveillance to confirm these findings. This is an example of how modern pharmacokinetic studies can improve risk assessment, making it easier to understand the epidemiological studies.
Examples of in vivo animal studies
In the past 2 years, many excellent in uiuo animal studies have been carried out. Two particular studies demonstrate the importance, differences, and the usefulness of animal studies as well as the difficulties inherent in drawing inferences from animal studies to describe human risk. Dam and c o a~t h o r s "~ used an in uiuo animal model to study the effect of chlorpyrifos (CPF), an organophosphate insecticide whose domestic use has been curtailed in the USA because of concerns about its neurotoxicity, on gene expression. Newborn animals were injected subcutaneously with one of two different doses of CPF on postnatal days 1 4 or 11-14. Studies of the forebrain using molecular biological techniques revealed a significant elevation in one protein that persisted for 5 days after cessation of the exposure regimen. This is an interesting study; however, the results are of little use in determining the human risks of CPF for the following reasons: 1 CPF exposure in humans does not occur via subcutaneous injection but by ingestion or skin absorption of contaminated food or water. 2 The serum concentration of CPF was not determined for the two different exposures used. 3 There was no discussion of the range of levels of CPF that have occurred in human populations. 4 The threshold dose and the no-observed adverse effect level (NOAEL) were not determined. 5 The authors performed toxicogenomics without toxicokinetics.
In contrast, the in uiuo study by Tyl and coauthors6%n the reproductive toxicity of dietary bisphenol in rats is considered to be a modern, animal toxicology study for the following reasons: . 1 The bisphenol was placed in the diet ad libitum.
2 There were seven exposure groups. 3 The exposures were listed in ppm and mdkg. 4 The range of exposures used was very' large: 0.001-500 mg/kg or a 500 000-fold range.
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The following were not affected a t any of the lower exposures although some effects were observed in the 500mg/kg group: mating, fertility, gestational indices, ovarian primordial follicle counts, estrous cyclicity, precoital interval, gestational length, offspring sex ratios, postnatal survival, nipplelareolae retention in pre-weanling males, epididymal sperm number, motility, and morphology, daily sperm production, and efficiency of production 6 The adult NOAEL was 5mg/kg/day and the reproductive NOAEL was SOmg/kg/day. There was a reduction in total body weight and some reduction in organ weight at the higher exposures.
To perform a risk analysis for bisphenol in the human population, some additional information is required that was not reported in this study but which is available in other studies. Yamada and coauthorsh7 obtained bisphenol exposure data in humans from the mother and amniotic fluid. The average concentration of bisphenol was 0.32ng/mL of serum, with a range of 0.0-1.6ng/mL, levels which appear to be far below the threshold exposure determined by Tyl and coauthors. However, Tyl and coauthors did not obtain the same pharmacokinetic data in the rat that Yamada and coauthors reported in the human, and therefore the serum concentration of bisphenol in the rat at the threshold exposure is not known. Furthermore, it is not known whether the metabolism and effects of bisphenol are similar in the human and the rat.
These studies"s6' on the risk analysis for bisphenol in the human population indicate the difficulties that can be faced in achieving an accurate and complete interpretation of the data. Combining such studies may appear to be a rare occurrence in the field of risk analysis; fortunately, however, it is occurring more often.6x
In vitro testing
In uitro tests can be utilized for preliminary screening procedures, and to study the mechanisms of teratogenesis and embryogenesis. However, in vitro studies will never be able to predict human teratogenic risks at particular exposures without additional data obtained from whole animal and epidemiological s t~d i e s .~~~~~~~~~~~
In spite of the advances in in uitro and in uiuo testing for teratogenicity, human epidemiological surveillance by various methodologies is, and will continue to be, our most powerful tool for discovering human reproductive toxins and teratogens. It may be difficult for experimental teratologists to accept the fact that alert physicians and scientists have been the most prominent contributors to the discovery of the environmental causes of birth defects.lh plete evaluation. This is also true if a pregnant woman is
The role of the physician in counseling exposed to a drug, chemical, or physical agent. ,As mentioned families regarding the etiology of -previously, only a small percentage of birth defects result from a child's congenital malformation exposure to prescribed drugs, chemicals, and physical agent^'^.^^ (Table 15. 
3). Even when the drug is listed as a ter-
The clinician must be cognizant of the fact that many patients believe that most congenital malformations are caused by a drug or medication taken during pregnancy. Counseling patients about reproductive risks requires a significant degree of knowledge and skill. Physicians must also realize that erroneous counseling by inexperienced health professionals may result in nonmeritorious litigation. ' Unfortunately, it has sometimes been assumed that if a drug or chemical causes birth defects in an animal model or in vitro system at a high dose, then it has the potential for producing birth defects at any This may be reinforced by the fact that many teratology studies reported in the literature investigate the effects of several doses but do not determine the no-effect dose.
Ignoring the basic tenets of teratology appears to occur most commonly in the evaluation of environmental toxic exposures when the exposure is very low or unknown, and the agent has been reported to be teratogenic a t a very high dose or a maternally toxic dose. In most instances, the actual population exposure is orders of magnitude helow the threshold dose, the doses that were used in animal studies, or those received during toxic exposures in the population. This has been the case with 2,4,5-trichlorophenoxyacetic acid (2,4,5-T), polychlorinated biphenyls (PCBs), lead, cadmium, arsenic, pesticides, herbicides, veterinary hormones, and industrial exposures.
Unfortunately, there are exaniples where environmental disasters have been responsible for birth defects or pregnancy loss in exposed populations (methyl mercury in Japan, PCBs in the Far East, organic mercury in the Middle East, and lead poisoning in the nineteenth and early twentieth centuries) and examples where teratogenic drugs have been inadvertently introduced (Table 15. 1 1) . Therefore, it is not possible to determine whether a chemical or drug is safe or hazardous unless the magnitude of the exposure is known.
Scholarly evaluation
The physician should respond to a parent's query into the cause of a child's birth defect using the same professional and methodical approach that would be used in a differential diagnosis for any clinical problem. Physicians have a protocol for evaluating complex clinical problems, for example, "fever of unknown origin," "failure to thrive," "congestive heart failure," or "respiratory distress." If a mother of a malformed infant had some type of exposure during pregnancy, for example, medication or a diagnostic radiological examination, the consulting physician should not support or suggest the possibility of a causal relationship before performing a comatogen, to exert a teratogenic effect it has to be administered during the sensitive period of development for that drug, and above the threshold dose. Furthermore, the malformations in a child should be the same as the malformations in the teratogenic syndrome produced by that particular drug. It should be emphasized that in a recent analysis of the 200 most prescribed drugs in the USA, none were found to have measurable teratogenic potential. 64 After a complete examination of the child and a review of the genetic and teratology medical literature, the clinician must decide whether the child's malformations are genetic or result from exposure to an environmental toxin or agent. It may not be possible to definitively or presumptively conclude the etiology of the child's birth defects. This information must then be conveyed to the patient in an objective and compassionate manner. A similar situation exists if a pregnant woman has been exposed to a drug, chemical, or physical agent, as the mother will want to know the risk of the exposure to her unborn child. A formal approach is recommended to determine whether a particular environmental drug, chemical or physical agent is a reproductive toxicant; this should include, where possible, data obtained from a number of investigative approaches (Table 15. 13'") including: (1) epidemiological studies,"*'" (2) secular trend or ecological trend analysis, (3) animal reproductive studies,27-" (4) dose-response relationships and pharmacokinetic, toxicokinetic, pharmacodynarnic, and toxicodynamic studies comparing human and animal metabolism, (5) MOA studies that pertain specifically to the agent and include receptor affinity, cytotoxicity, genoto-75 7X..10.12 xicity, organ toxicity, neurotoxicity, etc.,-.--(6) biological plausibility.
Some typical analyses of the reproductive risks of doxylamine succinate (Bendectin), sex steroids, diagnostic ultrasound, and electromagnetic fields demonstrate the usefulness of an organized approach to determine whether an environmental agent has been demonstrated to be a reproductive toxin.41,.5?-fl.6'l
Clinical evaluation
There are many articles and books that can assist the physician with the evaluation of the medical literature and the clinical evaluation of the patient,'""R.24.'X.5',.56-"' although training programs d o not usually prepare generalists to perform sophisticated genetic or teratology counseling. In addition to the ~~s u a l history and physical evaluation, the physician has to obtain information about the nature, magnitude, and timing of the exposure. The physical examination should include descriptive and quantitative inforn~ation about the physical Table 15 . 13 Proof of developmental toxicity in humans.
Epidemiological studies Controlled epidemiological studies consistently demonstrate an increased incidence of a particular spectrum of embryonic and/or fetal effects in exposed human populations Seculnr trend data Secular trends demonstrate a positive relationship between the changing exposures to a common environmental agent in human populations and the incidence of a particular embryonic andlor fetal effect
Animal developmental toxicity studies An.animal model that mimics the human developmental effect at clinically comparable exposures can be developed. Because mimicry may not occur in all animal species, animal models are more likely to be developed once there is good evidence for the embryotoxic effects reported in the human. Developmental toxicity studies in animals are indicative of a potential hazard in general rather than the potential for a specific adverse effect on the fetus when there are no human data on which to base the animal experinients Dose-response relationship (pharmacokinetics and toxicokinetics) Developmental toxicity in the human increases with dose (exposure), and the developmental toxicity in animals occurs at a dose that is pharmacokinetically (quantitatively) equivalent to the human exposure characteristics of the child. While some growth measurements are routine, many measurements taken by specialized counselors are not part of the usual physical examination, e.g., palpebral fissure size, ear length, intercanthal distances, and total height-to-trunk ratio. Important physical variations in facial, hand, and foot structure as well as other anatomical structures may be suggestive of known syndromes, either teratological or genetic.
Evaluation of the reproductive risk or cause of a child's malformation after an environmental exposure during pregnancy
The vast majority of consultations involving pregnancy exposures conclude that the exposure does not change the reproductive risks for that pregnancy. In many instances, the information that is available is so vague that the counselor cannot reach a definitive conclusion about the magnitude of the risk. The following information is necessary to evaluate any risk: 
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6 Is this a wanted pregnancy or is the family ambivalent about carrying this baby to term? 7 What is the medical and reproductive history of the mother with regard to prior pregnancies and the reproductive history of the family lineage?
After obtaining this information, the counselor is able to provide the family with an estimate of the reproductive risks of the exposure. Some examples of consultations that have been referred to our clinical teratology service are listed below.
Patient 1
A 34-year-old pregnant laboratory worker dropped and broke a reaction vessel containing a mixture of chemical reagents. She proceeded to clean the floor with paper towels and later became concerned about the potential harmful effects of the exposure. This was a planned, wanted pregnancy; she was in the sixth week of pregnancy and, therefore, the embryo was in the period of early organogenesis. The chemicals in the spill were tetrahydrofuran (70%), pyridine (20%), and iodine (1%). It was not possible to quantitatively estimate the exposure to these agents, but the laboratory worker experienced no symptoms from the exposure. There have been no epidemiological studies of tetrahydrofuran and pyridine in pregnant women but iodine has been shown to interfere with fetal thyroid development; in this situation, however, the exposure would have been inconsequential because, at this stage of pregnancy, the thyroid is not yet present. No other exposure to reproductive toxins occurred in this pregnancy and the family history for congenital malformations was negative. The woman was advised that it would be very unlikely that her DEVELOPMENTAL TOXICOLOGY, DRUGS, AND FETAL TERATOGENESIS teratogenic risk woi~ld be increased because the exposures to the embryo would be extremely low. She was told that she still faced the background risks for birth defects and miscarriage and, therefore, her reproductive risks would be the same as tl?at of the general population (Table 15 .1).
Patient 2
A 26-yeai-old pregnant woman was in an automobile accident in the 10th week of her pregnancy and sustained a severe concussion. Although she did not convulse post injury, the treating neurosurgeon prescribed 300mg of diphenylhydantoin during her first 24h in hospital. Fortunately, she recovered from the injury without any sequelae but her primary physician was concerned that she had received an anticonvulsant associated with a teratogenic syndrbme. No other exposure to reprocluctive toxins occurred in this pregnancy and the family history for congenital malformations was negative, except for an uncle with neurofibromatosis. The primary physician requested a consultation with regard to the teratogenic risk. While diphenylhydantoin administered chronically throughout pregnancy has been associated with a low incidence of characteristic facial dysmorphogenesis, reduced mentation, cleft palate, and digital hypoplasia, there are no data to indicate that 24 h of therapy would cause any of these features. In addition, the development of the lip and palate are complete by the 10th week of pregnancy. ?;his was a wanted pregnancy and the mother chose to continue her pregnancy; she delivered a normal 3370-g boy at term.
Patient 3
A 25-~ear-old woman was seen in the emergency service of her local hospital with nausea, vomiting, and diarrhea, on return from a cruise on which a number of the passengers became ill with similar symptoms. The emergency-ward physician ordered a pregnancy test followed by a flat-plate radiograph of the abdomen as there was evidence of peritoneal irritation; however, both of these tests were negative. One week later she missed her menstrual period and a subsequent pregnancy test was positive. Her obstetrician was concerned because she had been exposed to a radiological examination at a time when she was pregnant; he referred the patient for counseling after obtaining an ultrasound that indicated that the embryo was approximately 7 days post conception a t the time of the examination. The patient advised the counselor that she was ambivalent about the pregnancy because of the "dangers" of the X-rays to her embryo. The estimated exposure to the embryo was less than 500 mrad (O.OOSSv), an exposure that is far below that known to affect the developing embryo. Also, the embryo was exposed during the first 2 weeks post conception, a time that is less likely to increase the risk of teratogenesis, even at much higher exposure^.'^^" After an evaluation of the family history and after receiving counseling about the risks of the radiological examination, the woman decided to continue the pregnancy; she delivered a normal 3150-g baby.
Evaluation of the cause of a child's congenital malformations: unknown, genetic, or environmental
Patient 4
The mother of a 30-year-old man born in the Azores in 1960 with a congenital absence of the right leg below the ltnee had pursued compensation for her son because she was certain that she must have received thalidomide during her pregnancy. 4 The German manilfactilrer of thalidomide refused compensation, claiming that thalidomide had never been distributed in the Azores. The mother fervently believed that thalidomide was responsible for her son's malformations and asked for my opinion; she sent me the radiograph studies of his hips and l e~s and his complete evaluation performed at the local hospital in the Azores. He had none of the other stigmata of thalidomide embryopathy (preaxial limb defects, phoconielia, facial hemangioma, ear malformations, deafness, crocodile tears, ventricular septa1 defect, intestinal or gallbladder atresia, and kidney malformations) and, most importantly, his limb n~alformations were not of the thalidoniide type; he had a unilateral congenital amputation with no digital remnants at the end of the limb, his pelvic girdle was completely normal, and his limb defect involved only one leg with the other leg being normal. In this particular case, the man had a congenital amputation probably resulting from vascular disruption of an unknown etiology (known causes of vascular disruptive malformations are cocaine, misoprostol and chorionic villous sampling). It is difficult to determine whether any amount of appropriate counseling will give closure to this mother.
Patient 5
The family of a malformed boy claimed that the antinausea medication doxylamine succinate (Bendectin),s2"'-7' taken by the mother during pregnancy, was responsible for the child's congenital limb reduction defects. Bendectin was taken after the period of limb organogenesis; however, some limb 111al-formations can be produced by teratogens after this time. The boy's malformation was the classical split-hand, split-foot syndrome, which is donlinantly inherited; it was unaccompanied by any other dysmorphogenetic effects. Although significant number of cases of this syndrome result from a new mucation, neither parent manifested the malformation and this suggested that a new mutation had occurred in the sex cells of one of the parents. Therefore, the risk of this malformation occurring in the offspring of this boy would be 50%. It was concluded that Bendectin was not responsible for this child's malformation; however, in spite of the obvious genetic etiology of the birth defect, a legal suit was filed. A jury decided for the defendant, namely, that Bendectin was not responsible for the child's malformation.
Patient 6
A woman visited a hospital emergency ward with severe lower abdominal pain; as she had had a previous ectopic pregnancy that necessitated the removal of her ovary and Fallopian tube, she was seen by an obstetrical resident. A pregnancy test was positive and she returned to the obstetrical clinic a week later when her chorionic gonadotropin level was retested. It had -not changed from its previous level and, without performing I ' an ultrasound, a diagnosis of ectopic pregnancy was made; in order to preserve the patient's reproductive potential, it was decided to treat the ectopic pregnancy with methotrexate rather than remove the remaining fallopian tube and ovary. However, following the administration of methotrexate, a laboratory report was received which indicated that the gonadotropin level had increased fivefold, and a subsequent ultrasound revealed a normally implanted embryo; the laboratory report received earlier in the day was found to be a copy of the original report performed a week earlier. The mother was counseled that the baby was a t an increased risk of having congenital malformations because of the exposure to methotrexate; however, she refused to abort the pregnancy. The obstetrical departmelit therefore offered to provide care for the pregnancy and delivery that included a number of ultrasound examinations. At 28 weeks, the patient went into labor and delivered a premature liveborn infant, and during infancy, the child was diagnosed with hydrocephalus, developmental delay, and spastic cerebral symptomatology. The family filed a lawsuit against the doctors and hospital and I was asked to evaluate the allegation that the abnormalities in the child were due to the administration of methotrexate. Methotrexate has been reported to cause growth retardation, microcephaly, developmental delay, and hydrocephalus, but not prematurity. The clinical care provided by the resident doctor was unfortunate; however, the provision of care by the obstetrical department turned out to be fortunate for the defendants in this case. A review of the records revealed two important findings: first, an ultrasound examination taken a week before the premature delivery revealed that there was no evidence of hydrocephalus and, second, the birthweight was appropriate for the gestational stage. Therefore, the exposure to methotrexate was not responsible for the serious problems in this infant; the hydrocephalus and neurological symptoms resulted from a central nervous system (CNS) bleed in the postnatal period as a complication of the prematurity. These examples show that it is not a simple process to determine the reproductive risks of an exposure during pregnancy or to determine the etiology of a child's congenital malformations. It requires careful analysis of the medical and scientific literature on the reproductive toxic effects of exogenous agents in humans and animals, as well as an evaluation of the exposure and biological plausibility of an increased risk or a causal connection between the exposure and a child's congenital malformation. It also involves a careful physical examination, and a review of the scientific literature regarding the genetic and environmental causes of the malformations in question. Abridged counseling, based on superficial and incomplete analyses, is a disservice to the families .involved.
Conclusion
Approximately 10% of human malformations are due to environmental causes and fewer than 1% are related to prescription drug exposure, chemicals, or radiation. However, malformations caused by drugs and other therapeutic agents are important because these exposures may be preventable. Advances in animal research and epidemiology have enabled scientists to gain a better understanding of the mechanisms of teratogenesis.
Concerns about environmental chemicals and physical agents are clearly justified because, in most cases, not enough information is available on the potentially differential effects on the fetus and child. Such information, for example, the population exposure and the NOAEL, can only be obtained from high-quality human and animal toxicology and epidemiological studies which include toxicokinetic and toxicodynamic data and, therefore, it is essential that we expand our research programs in these areas. Ecological studies that do not measure exposures in the human population are more confusing than helpful in determining human risks, and study~ng exposures to groups of agents, e.g., solvents and pesticides, does not allow a risk assessment for individual toxicants.
All chemicals and drugs have the potential for developmental toxicity if the exposure is high enough; it would therefore be beneficial if humans were not exposed to chemicals in the workplace or home, or if chemicals were not dispersed into the environment. To address this problem now, and in the future, an extensive program of monitoring, reducing, and , eliminating the delivery of chemicals to the environment and the exposure of populations to chemicals is needed. Introducing or banning chemicals that expose the human population is an extremely difficult task that needs to be carefully planned on the basis of risks and benefits. nan risk a . . .
6 Labeling an environmental exposure as teratogenic is inappropriate unless one characterizes the exposure with regard to the dose, route of exposure, and stage of pregnancy when the exposure occurred. 7 The application of the basic scientific principles of teratology is extremely important in evaluating studies .. on the reproductive effects of an environmental agent.
These principles include the following criteria: exposure o teratogens follows a toxicological dose-response urve; the embryonic stage at which exposure occurs letermines what effects (if any) a teratogen has; most I eratogens have a confined group of congenital malformations (syndrome of agent's effects) and; no teratogen can produce every type of malformation. 17 In vitro tests can be used to study the mechanl. teratogenesis and embryogenesis, and for prelin screening procedures. However, in vitro studies predict human teratogenic risks at particular ex without the bene animal studies ar 1 8 The clinician mu patients believe tnat most congenlcal malrormarlons are caused by a drug pregnancy. 1 9 Ignoring the basic LcrIr;La vL r r r a~v~v~y appears to occur most commonly in the evaluation of environme exposures when the exposure was very low or unknown and the agent has been reported to b teratog dose, 20 The ev;
should (when posslme) use aata ootalnea rrom investigative approaches including: (1) epidemiological studies, (2) secular trend analysis, (3) animal reproductive studies, (4) dose-response relationshios.
mec )f action (MOA) stul specific : agent and include r cytotox )toxicity, organ toxic neurotoxlclcy, and (6) biologica! p~a~~l~l l l t y . . , , micals 9 The threshold dose for an environmental toxicant is the dose below which the incidence of death, malformation, growth retardation, or functional deficit is not greater than that of control subjects. The severity . and incidence of malformations produced by every exogenous agent that has been appropriately studied have exhibited threshold phenomena during organogenesis.
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